en · de · es · pt
liraglutide-notes.peptides6088.com › News › Cardarine As Investigational Pparδ Agonist — Worked Examples

Cardarine As Investigational Pparδ Agonist — Worked Examples

By Editorial Desk · published 2026-06-08 · last reviewed 2026-07-30 · News

PPARδ agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-07-30. Anything still debated is marked as such rather than presented as settled.

Cardarine as Investigational PPARδ Agonist

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Mechanism and Laboratory Detection

Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.

Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.

GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.

Cardarine at a glance

PropertyValueNotes
Common synonymsGW501516, GW-501516, GW 501516, endurobolNames vary in research and anti-doping documents.
Chemical classSynthetic PPARδ agonistSmall-molecule nuclear receptor ligand.
CAS Registry Number317318-70-0Identifier commonly associated with GW501516.
AppearanceWhite to off-white powderTypical for purified research material.
SolubilityLow in water; soluble in DMSO and ethanolOrganic solvents are common for laboratory stock solutions.

Identity and Pharmacological Classification

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Related pages on this site

Mechanism and Detection

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.

Background and Regulatory History

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Mechanism and Detection Methods

Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.

Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.

GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.

Notes from published material

Seeking revenge against Kruger for inheriting his father's dojo, Biskes attacks the Dekarangers for their badges on Agent Abrella's behalf as part of the latter's smear campaign against them until Biskes is deleted by Deka Master. Biskes is voiced by Takeshi Kusao (草尾 毅, Kusao Takeshi). Sukekonian Mashu (スケコ星人マシュー, Sukeko Seijin Mashū): A fox-themed con artist from Planet Sukeko who is charged with manipulating, marrying, and killing 273 women via Psycho Mushrooms. Posing as a human named Hironobu (ヒロノブ), he targets Umeko. However, a suspicious Sen-chan confronts Mashu, who unwittingly exposes himself while bragging about his intentions before being deleted by Deka Pink S.W.A.T. Mode. Mashu is voiced by Osamu Hosoi (細井 治, Hosoi Osamu) while his human form is portrayed by Hiroyuki Matsumoto (松本 博之, Matsumoto Hiroyuki). Dynamoian Terry X (ダイナモ星人テリーX, Dainamo Seijin Terī Ekkusu): An inductor-themed criminal from Planet Dynamo who possesses arm-mounted, weaponized coilguns and is charged with absorbing ESPers' life forces and converting them into plasma batteries to sell on the black market, having done so across 445 planets long before S.P.D. was founded and having already been approved for deletion. Fifteen years prior, he captured then-rookies Hoji and Jasmine and nearly killed them before the pair's partner Gyoku Rou saved them and seemingly deleted Terry X. Having survived, Terry X resurfaces in the present with upgraded batteries he bought from Agent Abrella to renew his attempt to absorb Jasmine's life force, only to be overpowered by the Dekarangers.

=== United States (1804) === On 29 April 1804, Alexander von Humboldt, accompanied by Bonpland and Monttfar, embarked from Havana on the Spanish frigate Concepcion en route to Philadelphia. They endured a week-long storm in the Bahama Straits, raising concerns for the safety of their scientific collections. After 24 days, they reached the calm waters of Delaware, where they had their first views of the United States. The landscape featured low, forest-covered shores punctuated with marshland, and as they neared Philadelphia, attractive farmhouses came into sight amidst the forest clearings. However, upon closer approach, the waterfront revealed an unsightly scene of wooden warehouses and refuse. Behind this façade lay a well-organized city of 75,000 residents, reminiscent of European towns. Its cobblestone streets lined with poplar trees, elegant three-storey red-brick houses, and well-furnished interiors stood in stark contrast to the initial impression. The main public building, aside from the State House, was Philosophic Hall, home to the American Philosophical Society, which played a crucial role in arranging for Humboldt's visit. Despite Philadelphia losing its capital status to Washington, it remained the cultural and scientific heart of the burgeoning republic. Humboldt and his companions were accommodated in an inn near the harbor on Market Street, and their arrival was promptly covered in the local newspapers.

The term "Soft Bodied" refers to animals which lack typical systems of skeletal support - included in these are most insect larvae and true worms. Animals that are soft bodied are constrained by the geometry and form of their bodies. However it is the geometry and form of their bodies that generate the forces they need to move. The structure of soft bodied skin can be characterized by a patterned fiber arrangement, which provides the shape and structure for a soft bodied animals. Internal to the patterned fiber layer is typically a liquid filled cavity, which is used to generate hydrostatic pressures for movement. Some animals that exhibit soft bodied locomotion include starfish, octopus, and flatworms.

Sheep fed by a diet containing bracken develop acute haemorrhagic disease and bright blindness. The main features of the blindness include progressive retinal atrophy and stenosis of the blood vessels. In 1993, Yamada group proved ptaquiloside was the compound causing retinal degeneration.

Sources: en.wikipedia.org

Background from the literature

"In 1990 members of the Bush administration ... cited Security Council resolutions as sufficient support for the President to act militarily against Iraq without congressional authority." A series of UN Security Council resolutions and Arab League resolutions were passed regarding Iraq's invasion of Kuwait. Resolution 678, passed on 29 November 1990, gave Iraq a withdrawal deadline until 15 January 1991 and authorized "all necessary means to uphold and implement Resolution 660", and a diplomatic formulation authorizing the use of force if Iraq failed to comply. To ensure the US received economic backing, James Baker went on an 11-day journey to nine countries in September 1990, which the press dubbed "The Tin Cup Trip". The first stop was Saudi Arabia, which had already granted permission to the US to use its facilities. Baker believed that Saudi Arabia should assume some of the cost of to defend it. When Baker asked King Fahd for $15 billion, the King agreed, with the promise that Baker ask Kuwait for the same amount. The next day, 7 September, Baker did just that, and the emir of Kuwait, displaced in a Sheraton hotel outside Kuwait, agreed. Baker moved to enter talks with Egypt, whose leadership he considered "the moderate voice of the Middle East". President Mubarak was furious with Saddam for his invasion, and that Saddam had assured Mubarak that an invasion was not his intention. Egypt received approximately $7 billion in debt forgiveness for providing support and troops for the US-led intervention.

The smaller size and single domain make these antibodies easier to transform into bacterial cells for bulk production, making them ideal for research purposes. Single-domain antibodies are being researched for multiple pharmaceutical applications, and have potential for use in the treatment of acute coronary syndrome, cancer, Alzheimer's disease, and COVID-19.

The oxygen stable isotope system is based on the 18O/16O (δ18O) ratio in a given material, which is enriched/depleted relative to a standard. The field typically normalizes to both Vienna Standard Mean Ocean Water (VSMOW) and Standard Light Antarctic Precipitation (SLAP). This system is famous for its use in paleoclimatic studies but it also a prominent source of information in bioarchaeology. Variations in δ18O values in skeletal remains are directly related to the isotopic composition of the consumer's body water. isotopic composition of mammalian body water is primarily controlled by consumed water. δ18O values of freshwater drinking sources vary due to mass fractionations related to mechanisms of the global water cycle. Evaporated water vapor is more enriched in 16O (isotopically lighter; more negative delta value) compared to the remaining water, which is depleted in 16O (isotopically heavier; more positive delta value). An accepted first-order approximation for the isotopic composition of animal drinking water is local precipitation, though this is complicated to varying degrees by confounding water sources like natural springs or lakes. The baseline δ18O used in archaeological studies is modified depending on the relevant environmental and historical context. δ18O values of bioapatite in human skeletal remains are assumed to have formed in equilibrium with body water, thus providing a species-specific relationship to oxygen isotopic composition of body water.

RNA interference (RNAi) is a biological process in which RNA molecules are involved in sequence-specific suppression of gene expression by double-stranded RNA, through translational or transcriptional repression. Historically, RNAi was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. The detailed study of each of these seemingly different processes elucidated that the identity of these phenomena were all actually RNAi. Andrew Fire and Craig Mello shared the 2006 Nobel Prize in Physiology or Medicine for their work on RNAi in the nematode worm Caenorhabditis elegans, which they published in 1998. Since the discovery of RNAi and its regulatory potentials, it has become evident that RNAi has immense potential in suppression of desired genes. RNAi is now known as precise, efficient, stable and better than antisense therapy for gene suppression. Antisense RNA produced intracellularly by an expression vector may be developed and find utility as novel therapeutic agents. Two types of small ribonucleic acid (RNA) molecules, microRNA (miRNA) and small interfering RNA (siRNA), are central to components to the RNAi pathway. Once mRNA is degraded, post-transcriptional silencing occurs as protein translation is prevented. Transcription can be inhibited via the pre-transcriptional silencing mechanism of RNAi, through which an enzyme complex catalyzes DNA methylation at genomic positions complementary to complexed siRNA or miRNA.

== Ligands == The AMYRs are bound by amylin with high affinity, and by calcitonin with relatively lower affinity. In humans, calcitonin gene-related peptide (CGRP) is a selective agonist with a greater affinity towards AMY1 than AMY3, while its affinity for AMY2 isn’t well understood. Drugs that mimic Amylin to activate amylin receptors (called Amylin receptor agonists) are being developed as therapies for diabetes and obesity, and one, pramlintide, has been FDA approved as a treatment for diabetes. CGRP receptor antagonists which are being developed for migraine, may also act as antagonists for AMY1, which could be playing a role in their effects. Dual agonists of the amylin and calcitonin receptors (DACRAs) are under development for obesity. Amylin and its receptors are believed to play a role in Alzheimer's disease.

Sources: en.wikipedia.org

Reference notes

== History == A number of types of fever were known as early as 460 BC to 370 BC when Hippocrates was practicing medicine including that due to malaria (tertian or every 2 days and quartan or every 3 days). It also became clear around this time that fever was a symptom of disease rather than a disease in and of itself. Infections presenting with fever were a major source of mortality in humans for about 200,000 years. Until the late nineteenth century, approximately half of all humans died from infections before the age of fifteen. An older term, febricula (a diminutive form of the Latin word for fever), was once used to refer to a low-grade fever lasting only a few days. This term fell out of use in the early 20th century, and the symptoms it referred to are now thought to have been caused mainly by various minor viral respiratory infections.

== Membership == After passage of the Eighteenth Constitutional Amendment in April 2010, it is mandatory for the Council to meet at least once in ninety days. Membership of the CCI consists of the following:

== History == The first low-cost spectrophotometer capable of recording an infrared spectrum was the Perkin-Elmer Infracord produced in 1957. This instrument covered the wavelength range from 2.5 μm to 15 μm (wavenumber range 4,000 cm−1 to 660 cm−1). The lower wavelength limit was chosen to encompass the highest known vibration frequency due to a fundamental molecular vibration. The upper limit was imposed by the fact that the dispersing element was a prism made from a single crystal of rock-salt (sodium chloride), which becomes opaque at wavelengths longer than about 15 μm; this spectral region became known as the rock-salt region. Later instruments used potassium bromide prisms to extend the range to 25 μm (400 cm−1) and caesium iodide 50 μm (200 cm−1). The region beyond 50 μm (200 cm−1) became known as the far-infrared region; at very long wavelengths it merges into the microwave region. Measurements in the far infrared needed the development of accurately ruled diffraction gratings to replace the prisms as dispersing elements, since salt crystals are opaque in this region. More sensitive detectors than the bolometer were required because of the low energy of the radiation. One such was the Golay detector. An additional issue is the need to exclude atmospheric water vapour because water vapour has an intense pure rotational spectrum in this region. Far-infrared spectrophotometers were cumbersome, slow and expensive.

Corin converts the atrial natriuretic peptide (ANP) precursor, pro-ANP, to mature ANP, a cardiac hormone that regulates salt-water balance and blood pressure. In mice, corin deficiency prevents pro-ANP processing and causes salt-sensitive hypertension. Corin may also function as a pro-brain-type natriuretic peptide convertase. Corin-mediated ANP production in the pregnant uterus promotes spiral artery remodeling and trophoblast invasion. CORIN mutations have been reported in patients with preeclampsia. In mice, corin functions in the dermal papilla to regulate coat color in an Agouti-dependent pathway.

P. Saraswathy, A.C. Dey, S.K. Sarkar, C. Kothalkar, P. Naskar, G. Arjun, S.S. Arora, A.K. Kohli, V. Meera, V. Venugopal and N.Ramamoorthy (2007). "99mTc generators for clinical use based on zirconium molybdate gel and (n, gamma) produced 99 Mo: Indian experience in the development and deployment of indigenous technology and processing facilities" (PDF). Proceedings of the 2007 International RERTR Meeting.{{cite journal}}: CS1 maint: multiple names: authors list (link) Iturralde MP (1 December 1996). "Molybdenum-99 production in South Africa". European Journal of Nuclear Medicine. 23 (12): 1681–1687. doi:10.1007/BF01249633. S2CID 28154691. Hansell C (1 July 2008). "Nuclear Medicine's Double Hazard: Imperiled Treatment and the Risk of Terrorism" (PDF). The Nonproliferation Review. 15 (2): 185–208. doi:10.1080/10736700802117270. S2CID 8559456. Archived from the original (PDF) on 18 July 2013. Retrieved 24 May 2012.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.

Is cardarine a steroid?

No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.

Why was cardarine not developed further?

Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.

How is cardarine detected in samples?

Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.

Network